Here's an uncomfortable truth about the software running most enterprise R&D organizations: it was never designed. It was accumulated.
An ELN bought in one decade, a LIMS in another, a PLM bolted on during a digital transformation push, each with its own data model, its own login, and its own version of the truth. The result isn't a platform. It's a pile.
That pile is now the biggest obstacle between R&D organizations and the AI-driven product development their executives are asking them to deliver. Comparing a modern R&D platform with legacy systems isn't a feature exercise. It's a question of whether your data can ever work as one asset.
What is a legacy R&D platform?
A legacy R&D platform is a set of separately built lab systems, typically an ELN, a LIMS, a QC system, and a PLM, connected by exports, emails, and manual re-entry instead of a shared data layer. Many were assembled by acquisition: a vendor bought a notebook product here and a sample-management product there, then put one brand over the top. The modules look unified in the sales deck, but underneath, the data never met.
The tell is simple. Ask where a single product's data lives, from first experiment to approved spec. If the answer involves four systems, a shared drive, and someone's inbox, you're running a legacy platform, whatever the logo says.
Why do legacy R&D platforms fail modern teams?
They fail because data fragments at every handoff, and modern product development is nothing but handoffs. Four structural problems show up almost everywhere.
They were built by acquisition, not architecture. When modules grew up as separate companies, each kept its own schema. "Integration" means file transfer, and every transfer strips context.
They're rigid where your products are complex. Generic sample tracking can't hold a real formulation (ingredients, amounts, order of addition, process steps) alongside the results those choices produced. For formulation-based industries, that's the whole story, and it doesn't fit.
They're expensive to stand still on. Version upgrades become consulting projects. Maintenance budgets defend the status quo instead of funding improvement.
Every handoff loses context. R&D sends work to QC by email. QC sends results to PLM by export. By the time a product reaches its spec, nobody can trace why it looks the way it does.
What do disconnected R&D systems actually cost?
More than the license fees suggest. The real costs hide in repeated work, failed scale-ups, and lost knowledge. When past experiments can't be found, teams spend roughly three months recreating work they've already done. When a shelved project becomes relevant again, restarting from zero can burn seven to eight months that access to the original data would have saved. And many scale-up failures that look like formulation problems are data problems: the process context that made something work in the lab never traveled with it to the plant.
What does a modern R&D platform do differently?
A modern R&D platform puts research, quality, and product lifecycle data in one structured layer, so a change made anywhere filters everywhere. In practice, that looks like data you can query by content: search by molecule, ingredient, application, or concentration range rather than by file names like "AS-6-8-26-114."
It means the formulation is linked to its results: recipe, process, and test data live on one record, so correlation takes minutes instead of an export marathon. Full instrument output is preserved, with curves and spectra kept intact next to the analysis instead of being flattened to a single number. Most systems store the answer. A modern platform stores the evidence. Quality data goes live, with control charts updating as results are entered rather than at month-end. And handoffs happen without re-entry: R&D sends a test request in-platform, QC sees it with full formulation context, and approved work moves to PLM with a click.
Just as important is what a modern platform deliberately doesn't do. It doesn't replace your ERP. Production planning, procurement, and finance stay exactly where they belong. The valuable flow runs the other way: the latest production recipe stays available to the scientists who will start their next project from it.
Where does AI fit in a modern R&D platform?
Last, and that's the point. AI on fragmented data is a demo. AI on structured, connected history is a capability. You can't run meaningful models on spreadsheets stitched together with VLOOKUPs. The organizations whose AI initiatives survive contact with production are the ones that structured their R&D, QC, and PLM data first. Structure first. AI second.
How do you tell modern from legacy in an evaluation?
Ask for proof, not promises. Have the vendor show one record traveling from R&D through QC to PLM without an export. Have them store a complete recipe (ingredients, amounts, process steps) as data, not as an attached document. Have them put a raw instrument curve next to the result it produced. Then ask what data their AI features actually run on.
A legacy stack fails these tests in the first ten minutes. A modern R&D platform makes them look boring.
The bottom line
Legacy R&D platforms aren't broken because they're old. They're broken because they were never one thing, and product development is. Replacing them is a data architecture decision.
See what a unified R&D, QC, and PLM platform looks like with your own products in it: book a demo
.png)
.png)
.png)
